首页 > 最新文献

Texas Heart Institute Journal最新文献

英文 中文
A Dedicated Device for Inside-Out Central Venous Catheterization. 用于内向外中心静脉导管插入术的专用设备。
IF 0.9 4区 医学 Pub Date : 2024-04-17 DOI: 10.14503/THIJ-23-8348
Bright Benfor, Eric K Peden
{"title":"A Dedicated Device for Inside-Out Central Venous Catheterization.","authors":"Bright Benfor, Eric K Peden","doi":"10.14503/THIJ-23-8348","DOIUrl":"https://doi.org/10.14503/THIJ-23-8348","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":" 18","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140691305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Percutaneous Thoracic Duct Embolization for Chylothorax After Total Arch Replacement. 经皮胸导管栓塞治疗全弓置换术后乳糜胸获得成功。
IF 0.9 4区 医学 Pub Date : 2024-04-16 DOI: 10.14503/THIJ-22-8077
Fumihiro Kitashima, Naohiro Shimada, Yojiro Machii, Masashi Tanaka
Chylothorax after cardiac surgery is a rare complication associated with severe morbidity and mortality. This report documents successful treatment with percutaneous thoracic duct embolization for chylothorax after total arch replacement. A 69-year-old man underwent replacement of the aortic arch to treat a ruptured aortic aneurysm. After surgery, the left thoracic drain discharged 2,000 to 3,000 mL serosanguineous fluid per day, even though the patient took nothing orally and was administered subcutaneous octreotide therapy. On postoperative day 9, percutaneous thoracic duct embolization was performed, and the drain could be removed. The chylothorax did not recur, and the patient was discharged on postoperative day 17.
心脏手术后的乳糜胸是一种罕见的并发症,具有严重的发病率和死亡率。本报告记录了经皮胸导管栓塞治疗全弓置换术后乳糜胸的成功案例。一名 69 岁的男性接受了主动脉弓置换术,以治疗破裂的主动脉瘤。术后,左胸腔引流管每天排出 2,000 至 3,000 毫升血清脓液,尽管患者没有口服任何药物,也没有接受皮下注射奥曲肽治疗。术后第 9 天,进行了经皮胸导管栓塞术,引流管得以拔出。乳糜胸没有复发,患者于术后第17天出院。
{"title":"Successful Percutaneous Thoracic Duct Embolization for Chylothorax After Total Arch Replacement.","authors":"Fumihiro Kitashima, Naohiro Shimada, Yojiro Machii, Masashi Tanaka","doi":"10.14503/THIJ-22-8077","DOIUrl":"https://doi.org/10.14503/THIJ-22-8077","url":null,"abstract":"Chylothorax after cardiac surgery is a rare complication associated with severe morbidity and mortality. This report documents successful treatment with percutaneous thoracic duct embolization for chylothorax after total arch replacement. A 69-year-old man underwent replacement of the aortic arch to treat a ruptured aortic aneurysm. After surgery, the left thoracic drain discharged 2,000 to 3,000 mL serosanguineous fluid per day, even though the patient took nothing orally and was administered subcutaneous octreotide therapy. On postoperative day 9, percutaneous thoracic duct embolization was performed, and the drain could be removed. The chylothorax did not recur, and the patient was discharged on postoperative day 17.","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"8 25","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140696188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coronary Artery Bypass Grafting in a Patient With Multivessel Disease and Dextrocardia With Situs Inversus Totalis. 为一名患有多支血管疾病和右心室突出并伴有完全性病变的患者实施冠状动脉旁路移植术
IF 0.9 4区 医学 Pub Date : 2024-04-16 DOI: 10.14503/THIJ-23-8382
Rohit Shahani, Adham Ahmed, Frank M Rosell, Alexander Iribarne
Dextrocardia with situs inversus totalis is a rare hereditary condition characterized by reversed orientation of the major thoracic and abdominal organs. Though dextrocardia itself is not believed to increase the risk of coronary artery disease, the workup and surgical management of patients with this condition may be technically challenging to heart team clinicians. This report describes the case management of a high-risk 56-year-old man with dextrocardia who presented with multivessel coronary artery disease.
右心室突出伴全坐位综合征是一种罕见的遗传性疾病,其特点是主要胸腔和腹腔器官的方向相反。虽然人们认为右心室突出症本身不会增加冠状动脉疾病的风险,但对心脏团队的临床医生来说,这种疾病患者的检查和手术治疗可能在技术上具有挑战性。本报告描述了一名 56 岁高危男性右心室扩张症患者的病例治疗,该患者伴有多支冠状动脉疾病。
{"title":"Coronary Artery Bypass Grafting in a Patient With Multivessel Disease and Dextrocardia With Situs Inversus Totalis.","authors":"Rohit Shahani, Adham Ahmed, Frank M Rosell, Alexander Iribarne","doi":"10.14503/THIJ-23-8382","DOIUrl":"https://doi.org/10.14503/THIJ-23-8382","url":null,"abstract":"Dextrocardia with situs inversus totalis is a rare hereditary condition characterized by reversed orientation of the major thoracic and abdominal organs. Though dextrocardia itself is not believed to increase the risk of coronary artery disease, the workup and surgical management of patients with this condition may be technically challenging to heart team clinicians. This report describes the case management of a high-risk 56-year-old man with dextrocardia who presented with multivessel coronary artery disease.","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"30 25","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140696135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular Disease Management With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Cardiology Primer. 2 型糖尿病患者使用葡萄糖钠转运体-2 抑制剂治疗心血管疾病:心脏病学入门。
IF 0.9 4区 医学 Pub Date : 2024-04-09 DOI: 10.14503/THIJ-23-8375
Allan Zhang, Ramsey Kalil, Alexander Marzec, Stephanie A Coulter, Salim S Virani, Kershaw V Patel, Matthew W. Segar
Patients with type 2 diabetes face an elevated risk of cardiovascular disease. This review centers on sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of drugs that, according to a growing body of evidence, may have major potential for managing cardiovascular disease in patients with type 2 diabetes. This review presents findings from multiple clinical trials suggesting that SGLT2 inhibitors can not only serve as preventive therapeutic agents but also play a role in the active management of heart failure. The discussion includes the mechanism of action of SGLT2 inhibitors, emphasizing that they enhance urinary glucose excretion, which could lead to improved glycemic control and contribute to metabolic shifts beneficial to cardiac function. Alongside these cardiometabolic effects, safety concerns and practical considerations for prescribing these agents are addressed, taking into account potential adverse effects such as genitourinary infections and diabetic ketoacidosis as well as the financial implications for patients. Despite these drawbacks, therapeutic indications for SGLT2 inhibitors continue to expand, including for kidney protection, although further research is necessary to fully understand the mechanisms driving the cardioprotective and kidney-protective effects of SGLT2 inhibitors. By synthesizing current knowledge, this review intends to inform and guide clinical decision-making, thereby enhancing cardiovascular disease outcomes in patients with type 2 diabetes.
2 型糖尿病患者罹患心血管疾病的风险较高。本综述以钠糖共转运体-2(SGLT2)抑制剂为中心,根据越来越多的证据,这类药物在控制 2 型糖尿病患者的心血管疾病方面具有重大潜力。本综述介绍了多项临床试验的结果,这些结果表明 SGLT2 抑制剂不仅可以作为预防性治疗药物,还可以在积极治疗心力衰竭方面发挥作用。讨论包括 SGLT2 抑制剂的作用机制,强调它们能促进尿糖排泄,从而改善血糖控制,促进有利于心脏功能的代谢转变。除了这些心脏代谢效应外,还讨论了处方这些药物的安全性问题和实际考虑因素,考虑到了潜在的不良反应,如泌尿生殖系统感染和糖尿病酮症酸中毒,以及对患者的经济影响。尽管存在这些缺点,SGLT2 抑制剂的治疗适应症仍在继续扩大,包括肾脏保护,但要充分了解 SGLT2 抑制剂的心脏保护和肾脏保护作用的驱动机制,还需要进一步的研究。本综述通过对现有知识的总结,旨在为临床决策提供信息和指导,从而改善 2 型糖尿病患者的心血管疾病预后。
{"title":"Cardiovascular Disease Management With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Cardiology Primer.","authors":"Allan Zhang, Ramsey Kalil, Alexander Marzec, Stephanie A Coulter, Salim S Virani, Kershaw V Patel, Matthew W. Segar","doi":"10.14503/THIJ-23-8375","DOIUrl":"https://doi.org/10.14503/THIJ-23-8375","url":null,"abstract":"Patients with type 2 diabetes face an elevated risk of cardiovascular disease. This review centers on sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of drugs that, according to a growing body of evidence, may have major potential for managing cardiovascular disease in patients with type 2 diabetes. This review presents findings from multiple clinical trials suggesting that SGLT2 inhibitors can not only serve as preventive therapeutic agents but also play a role in the active management of heart failure. The discussion includes the mechanism of action of SGLT2 inhibitors, emphasizing that they enhance urinary glucose excretion, which could lead to improved glycemic control and contribute to metabolic shifts beneficial to cardiac function. Alongside these cardiometabolic effects, safety concerns and practical considerations for prescribing these agents are addressed, taking into account potential adverse effects such as genitourinary infections and diabetic ketoacidosis as well as the financial implications for patients. Despite these drawbacks, therapeutic indications for SGLT2 inhibitors continue to expand, including for kidney protection, although further research is necessary to fully understand the mechanisms driving the cardioprotective and kidney-protective effects of SGLT2 inhibitors. By synthesizing current knowledge, this review intends to inform and guide clinical decision-making, thereby enhancing cardiovascular disease outcomes in patients with type 2 diabetes.","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"22 4","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140726637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distal Extent of Resection in Type A Dissection: Keeping It Simple. A 型解剖的远端切除范围:化繁为简。
IF 0.9 4区 医学 Pub Date : 2024-03-21 DOI: 10.14503/THIJ-23-8371
Marc R Moon, Puja Kachroo
{"title":"Distal Extent of Resection in Type A Dissection: Keeping It Simple.","authors":"Marc R Moon, Puja Kachroo","doi":"10.14503/THIJ-23-8371","DOIUrl":"10.14503/THIJ-23-8371","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"51 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Periprocedural Risk Predictors Affecting Long-Term Prognosis in Patients With Chronic Obstructive Pulmonary Disease Undergoing Coronary Artery Bypass Grafting. 影响冠状动脉旁路移植术慢性阻塞性肺病患者长期预后的围手术期风险预测因子
IF 0.9 4区 医学 Pub Date : 2024-03-18 DOI: 10.14503/THIJ-23-8199
Aleksander Dokollari, Serge Sicouri, Leila Hosseinian, Ozgun Erten, Basel Ramlawi, Gianluigi Bisleri, Massimo Bonacchi, Noah Sicouri, Gianluca Torregrossa, Francis P Sutter

Objective: This study sought to identify periprocedural risk predictors that affect long-term prognosis in patients with chronic obstructive pulmonary disease (COPD) undergoing isolated coronary artery bypass grafting (CABG).

Methods: All consecutive 4,871 patients undergoing isolated CABG between May 2005 and June 2021 were included. Patients with and without COPD were compared for baseline demographics and preoperative characteristics. A propensity-matched analysis was used to compare the 2 groups. The primary outcome was long-term incidence of all-cause death.

Results: After matching, 767 patients each were included in the COPD and non-COPD groups; mean age was 71.6 and 71.4 years (P = .7), respectively; 29.3% and 32% (P = .2) were women, respectively. Intraoperatively, median (IQR) operating room time was higher in the COPD group than in the non-COPD group (5.9 [5.2-7.0] hours vs 5.8 [5.1-6.7] hours, respectively; P = .01). Postoperatively, intensive care unit stay (P = .03), hospital length of stay (P = .0004), and fresh frozen plasma transfusion units (P = .012) were higher in the COPD group than in the non-COPD group. Thirty-day mortality was not different between groups (1.3% in the COPD group vs 1% in the non-COPD group; P = .4). Median follow-up time was 4.0 years. The rate of all-cause death was higher in the COPD group than in the non-COPD group (138 patients [18.3%] vs 109 patients [14.5%], respectively; P = .042). Periprocedural risk predictors for all-cause death in patients with COPD were atrial fibrillation, diabetes, male sex, dialysis, ejection fraction less than 50%, peripheral vascular disease, and Society of Thoracic Surgeons Predicted Risk of Mortality score greater than 4%.

Conclusion: Patients with COPD undergoing isolated CABG had a significantly higher incidence of all-cause death than those without COPD. Herein, risk predictors are provided for all-cause death in patients undergoing isolated CABG.

研究目的本研究旨在确定影响接受孤立冠状动脉旁路移植术(CABG)的慢性阻塞性肺病(COPD)患者长期预后的围手术期风险预测因素:方法:纳入2005年5月至2021年6月期间连续接受分离式冠状动脉旁路移植术的4871名患者。对患有和未患有慢性阻塞性肺病的患者进行基线人口统计学和术前特征比较。采用倾向匹配分析对两组患者进行比较。主要结果是全因死亡的长期发生率:匹配后,慢性阻塞性肺病组和非慢性阻塞性肺病组各有 767 名患者;平均年龄分别为 71.6 岁和 71.4 岁(P = .7);女性分别占 29.3% 和 32% (P = .2)。术中,慢性阻塞性肺病组的手术室时间中位数(IQR)高于非慢性阻塞性肺病组(分别为 5.9 [5.2-7.0] 小时 vs 5.8 [5.1-6.7] 小时;P = .01)。术后,慢性阻塞性肺病组的重症监护室住院时间(P = .03)、住院时间(P = .0004)和新鲜冰冻血浆输注单位(P = .012)均高于非慢性阻塞性肺病组。慢性阻塞性肺病组与非慢性阻塞性肺病组的 30 天死亡率没有差异(慢性阻塞性肺病组为 1.3%,非慢性阻塞性肺病组为 1%;P = .4)。中位随访时间为 4.0 年。慢性阻塞性肺病组的全因死亡率高于非慢性阻塞性肺病组(分别为 138 名患者 [18.3%] vs 109 名患者 [14.5%];P = .042)。COPD患者全因死亡的围手术期风险预测因素包括心房颤动、糖尿病、男性、透析、射血分数小于50%、外周血管疾病以及胸外科医师协会预测死亡风险评分大于4%:结论:接受孤立CABG手术的慢性阻塞性肺病患者的全因死亡发生率明显高于非慢性阻塞性肺病患者。本文提供了接受孤立的 CABG 患者全因死亡的风险预测指标。
{"title":"Periprocedural Risk Predictors Affecting Long-Term Prognosis in Patients With Chronic Obstructive Pulmonary Disease Undergoing Coronary Artery Bypass Grafting.","authors":"Aleksander Dokollari, Serge Sicouri, Leila Hosseinian, Ozgun Erten, Basel Ramlawi, Gianluigi Bisleri, Massimo Bonacchi, Noah Sicouri, Gianluca Torregrossa, Francis P Sutter","doi":"10.14503/THIJ-23-8199","DOIUrl":"10.14503/THIJ-23-8199","url":null,"abstract":"<p><strong>Objective: </strong>This study sought to identify periprocedural risk predictors that affect long-term prognosis in patients with chronic obstructive pulmonary disease (COPD) undergoing isolated coronary artery bypass grafting (CABG).</p><p><strong>Methods: </strong>All consecutive 4,871 patients undergoing isolated CABG between May 2005 and June 2021 were included. Patients with and without COPD were compared for baseline demographics and preoperative characteristics. A propensity-matched analysis was used to compare the 2 groups. The primary outcome was long-term incidence of all-cause death.</p><p><strong>Results: </strong>After matching, 767 patients each were included in the COPD and non-COPD groups; mean age was 71.6 and 71.4 years (P = .7), respectively; 29.3% and 32% (P = .2) were women, respectively. Intraoperatively, median (IQR) operating room time was higher in the COPD group than in the non-COPD group (5.9 [5.2-7.0] hours vs 5.8 [5.1-6.7] hours, respectively; P = .01). Postoperatively, intensive care unit stay (P = .03), hospital length of stay (P = .0004), and fresh frozen plasma transfusion units (P = .012) were higher in the COPD group than in the non-COPD group. Thirty-day mortality was not different between groups (1.3% in the COPD group vs 1% in the non-COPD group; P = .4). Median follow-up time was 4.0 years. The rate of all-cause death was higher in the COPD group than in the non-COPD group (138 patients [18.3%] vs 109 patients [14.5%], respectively; P = .042). Periprocedural risk predictors for all-cause death in patients with COPD were atrial fibrillation, diabetes, male sex, dialysis, ejection fraction less than 50%, peripheral vascular disease, and Society of Thoracic Surgeons Predicted Risk of Mortality score greater than 4%.</p><p><strong>Conclusion: </strong>Patients with COPD undergoing isolated CABG had a significantly higher incidence of all-cause death than those without COPD. Herein, risk predictors are provided for all-cause death in patients undergoing isolated CABG.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"51 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endovascular Strategies for Aortic Arch When US Food and Drug Administration-Approved Devices Are Not Available. 当无法获得美国食品和药物管理局批准的设备时,主动脉弓的血管内治疗策略。
IF 0.9 4区 医学 Pub Date : 2024-03-14 DOI: 10.14503/THIJ-24-8391
Gabrielle Sutton, Rana Afifi
{"title":"Endovascular Strategies for Aortic Arch When US Food and Drug Administration-Approved Devices Are Not Available.","authors":"Gabrielle Sutton, Rana Afifi","doi":"10.14503/THIJ-24-8391","DOIUrl":"10.14503/THIJ-24-8391","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"51 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140121112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resolution of Severe Portopulmonary Hypertension With Inhaled Treprostinil and Liver Transplantation. 通过吸入曲普瑞替尼和肝移植缓解严重的肺门高压症
IF 0.9 4区 医学 Pub Date : 2024-03-14 DOI: 10.14503/THIJ-23-8209
Alex J Chang, Choon Hwa Goh

Portopulmonary hypertension is a rare condition with a poor prognosis. Prompt management is essential for liver transplantation eligibility, a potentially curative option. This report presents a case of severe portopulmonary hypertension that resolved with a conservative therapeutic regimen of tadalafil, macitentan, and inhaled treprostinil, which ultimately enabled successful liver transplantation. There was no recurrence of pulmonary hypertension after transplantation, and the patient was weaned off most pulmonary arterial hypertension therapies. This case report is the first to provide evidence that inhaled treprostinil is a safe and effective alternative to continuous intravenous prostacyclins in portopulmonary hypertension.

肺动脉高压是一种罕见的疾病,预后不良。及时处理对获得肝移植资格至关重要,而肝移植是一种潜在的治疗方案。本报告介绍了一例严重的门静脉肺动脉高压患者,该患者在接受了他达拉非、马西坦坦和吸入曲普瑞替尼的保守治疗方案后,病情得到缓解,最终成功进行了肝移植。移植后,肺动脉高压没有复发,患者也脱离了大部分肺动脉高压治疗。本病例报告首次提供了证据,证明吸入曲普瑞替尼可安全有效地替代持续静脉注射前列环素治疗门静脉肺动脉高压。
{"title":"Resolution of Severe Portopulmonary Hypertension With Inhaled Treprostinil and Liver Transplantation.","authors":"Alex J Chang, Choon Hwa Goh","doi":"10.14503/THIJ-23-8209","DOIUrl":"10.14503/THIJ-23-8209","url":null,"abstract":"<p><p>Portopulmonary hypertension is a rare condition with a poor prognosis. Prompt management is essential for liver transplantation eligibility, a potentially curative option. This report presents a case of severe portopulmonary hypertension that resolved with a conservative therapeutic regimen of tadalafil, macitentan, and inhaled treprostinil, which ultimately enabled successful liver transplantation. There was no recurrence of pulmonary hypertension after transplantation, and the patient was weaned off most pulmonary arterial hypertension therapies. This case report is the first to provide evidence that inhaled treprostinil is a safe and effective alternative to continuous intravenous prostacyclins in portopulmonary hypertension.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"51 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140121113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Suture-Free Repair of Left Ventricular Rupture Using the EVARREST Patch. 使用 EVARREST 补片成功完成左心室破裂的无缝合修复术
IF 0.9 4区 医学 Pub Date : 2024-03-07 DOI: 10.14503/THIJ-23-8277
Paighton C Miller, Linda J Schulte, Kunal Kotkar

Left ventricular free wall rupture is a lethal complication of myocardial infarction. Although emergent surgical repair is the treatment of choice, the method of repair remains highly individualized. This report presents a case of spontaneous coronary artery dissection in a patient with Turner syndrome that led to left ventricular free wall rupture and was successfully repaired on cardiopulmonary bypass using a suture-free technique with the EVARREST Fibrin Sealant Patch.

左心室游离壁破裂是心肌梗死的致命并发症。尽管紧急手术修复是首选治疗方法,但修复方法仍高度个性化。本报告介绍了一例特纳综合征患者自发性冠状动脉夹层导致左心室游离壁破裂的病例,该患者在心肺旁路手术中使用 EVARREST 纤维蛋白密封补片无缝合技术成功修复了左心室游离壁。
{"title":"Successful Suture-Free Repair of Left Ventricular Rupture Using the EVARREST Patch.","authors":"Paighton C Miller, Linda J Schulte, Kunal Kotkar","doi":"10.14503/THIJ-23-8277","DOIUrl":"10.14503/THIJ-23-8277","url":null,"abstract":"<p><p>Left ventricular free wall rupture is a lethal complication of myocardial infarction. Although emergent surgical repair is the treatment of choice, the method of repair remains highly individualized. This report presents a case of spontaneous coronary artery dissection in a patient with Turner syndrome that led to left ventricular free wall rupture and was successfully repaired on cardiopulmonary bypass using a suture-free technique with the EVARREST Fibrin Sealant Patch.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"51 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140060911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How to Assess the Feasibility of a Second Transcatheter Aortic Valve Replacement When the First Valve Fails. 当第一次主动脉瓣置换术失败时,如何评估第二次经导管主动脉瓣置换术的可行性?
IF 0.9 4区 医学 Pub Date : 2024-02-13 DOI: 10.14503/THIJ-23-8301
Stephanie Tom, John Lisko, Kendra J Grubb
{"title":"How to Assess the Feasibility of a Second Transcatheter Aortic Valve Replacement When the First Valve Fails.","authors":"Stephanie Tom, John Lisko, Kendra J Grubb","doi":"10.14503/THIJ-23-8301","DOIUrl":"10.14503/THIJ-23-8301","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"51 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139724589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Texas Heart Institute Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1